River Wealth Advisors LLC Increases Holdings in Stryker Corporation $SYK

River Wealth Advisors LLC increased its position in shares of Stryker Corporation (NYSE:SYK) by 7.5% in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 29,350 shares of the medical technology company’s stock after purchasing an additional 2,048 shares during the quarter. Stryker accounts for approximately 0.8% of River Wealth Advisors LLC’s investment portfolio, making the stock its 29th largest holding. River Wealth Advisors LLC’s holdings in Stryker were worth $9,241,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of SYK. SmartHarvest Portfolios LLC increased its holdings in Stryker by 9.1% in the 2nd quarter. SmartHarvest Portfolios LLC now owns 1,413 shares of the medical technology company’s stock worth $445,000 after buying an additional 118 shares during the period. Ascent Group LLC lifted its stake in Stryker by 17.1% during the 2nd quarter. Ascent Group LLC now owns 15,162 shares of the medical technology company’s stock valued at $4,774,000 after acquiring an additional 2,211 shares during the period. Summit Securities Group LLC lifted its stake in Stryker by 1,296.5% during the 2nd quarter. Summit Securities Group LLC now owns 796 shares of the medical technology company’s stock valued at $251,000 after acquiring an additional 739 shares during the period. TCW Group Inc. boosted its holdings in shares of Stryker by 1.8% in the 2nd quarter. TCW Group Inc. now owns 6,084 shares of the medical technology company’s stock valued at $1,915,000 after acquiring an additional 109 shares during the last quarter. Finally, Marco Investment Management LLC increased its stake in shares of Stryker by 1.5% in the second quarter. Marco Investment Management LLC now owns 57,471 shares of the medical technology company’s stock worth $18,094,000 after acquiring an additional 834 shares during the period. Institutional investors and hedge funds own 77.09% of the company’s stock.

Stryker Stock Performance

SYK opened at $338.80 on Friday. The company has a debt-to-equity ratio of 0.59, a current ratio of 2.16 and a quick ratio of 1.33. The firm has a fifty day moving average price of $324.61 and a 200 day moving average price of $333.57. Stryker Corporation has a 1 year low of $281.00 and a 1 year high of $396.86. The stock has a market cap of $129.95 billion, a P/E ratio of 35.11, a P/E/G ratio of 2.17 and a beta of 0.76.

Stryker (NYSE:SYK) last released its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 EPS for the quarter, beating the consensus estimate of $3.49 by $0.20. The company had revenue of $6.59 billion for the quarter, compared to analyst estimates of $6.58 billion. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business earned $3.13 earnings per share. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Equities research analysts anticipate that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be paid a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.0%. The ex-dividend date of this dividend is Wednesday, September 30th. Stryker’s dividend payout ratio is presently 36.48%.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on SYK. BMO Capital Markets began coverage on shares of Stryker in a report on Wednesday, July 8th. They set an “outperform” rating and a $369.00 target price for the company. Wolfe Research downgraded Stryker from an “outperform” rating to a “peer perform” rating in a research report on Thursday. BTIG Research reduced their price objective on Stryker from $371.00 to $358.00 and set a “buy” rating for the company in a research note on Friday, July 31st. Royal Bank Of Canada decreased their price objective on Stryker from $435.00 to $420.00 and set an “outperform” rating for the company in a report on Friday, July 31st. Finally, JPMorgan Chase & Co. lowered their target price on Stryker from $400.00 to $350.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. One investment analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the company. According to data from MarketBeat.com, Stryker has an average rating of “Moderate Buy” and a consensus target price of $386.28.

Insider Transactions at Stryker

In other news, VP Robert S. Fletcher sold 4,544 shares of the firm’s stock in a transaction dated Thursday, May 28th. The stock was sold at an average price of $306.87, for a total transaction of $1,394,417.28. Following the sale, the vice president directly owned 10,582 shares in the company, valued at $3,247,298.34. This trade represents a 30.04% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Ronda E. Stryker sold 310,000 shares of Stryker stock in a transaction dated Tuesday, May 26th. The shares were sold at an average price of $312.23, for a total value of $96,791,300.00. Following the completion of the transaction, the director owned 1,924,880 shares of the company’s stock, valued at approximately $601,005,282.40. This represents a 13.87% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.60% of the stock is owned by company insiders.

Stryker Profile

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.